Antigen News and Research

RSS

Scientists develop olfactory fingerprint test to identify individuals from sense of smell

Each of us has, in our nose, about six million smell receptors of around four hundred different types. The distribution of these receptors varies from person to person - so much so that each person's sense of smell may be unique.

1 Jul 2015

Hepatic ALT flares linked to HBsAg clearance

Hepatic alanine aminotransferase flares are associated with rapid decline and greater annual reductions of hepatitis B surface antigen in patients with chronic hepatitis B virus infection who achieve HBsAg seroclearance, say Japanese researchers.

30 Jun 2015

Asterias Biotherapeutics added to Russell indexes

Asterias Biotherapeutics, Inc., a biotechnology company focused on the emerging field of regenerative medicine, today announced that it has been added to the Russell 2000, Russell 3000, Russell Global and Russell Microcap indexes following Russell Investments' ("Russell") reconstitution of its comprehensive set of U.S. and global equity indexes after the close of the U.S. markets on June 26, 2015.

30 Jun 2015

SLU's Center for Vaccine Development receives $2.9 million to study new vaccine to combat TB

Saint Louis University's Center for Vaccine Development has received a $2.9 million award from the Bill & Melinda Gates Foundation to study a new tuberculosis vaccine.

30 Jun 2015

Exhausted army of immune cells may damage the very body they are supposed to protect

An 'exhausted' army of immune cells may not be able to fight off infection, but if its soldiers fight too hard they risk damaging the very body they are meant to be protecting, suggests new research from the University of Cambridge.

30 Jun 2015

$FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease$

FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell’s Investigational New Drug application for the company’s lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn’s disease.

30 Jun 2015

Study opens up new line of research into origin of digestive diseases

There are numerous studies related to the absorption of nutrients from the stomach since understanding what happens in our digestive system is crucial, for example, in order to be able to avoid in the future some of the diseases that affect part of the population to a lesser or greater extent.

29 Jun 2015

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced updates on its lead product candidates, XmAb®5871 and XmAb®7195, and on its XmAb® bispecific oncology pipeline.

26 Jun 2015

Ebola diagnosis now possible within minutes

The Lancet has published details of a new point-of-care test for Ebola virus that is as sensitive as the conventional laboratory test, but provides results within minutes.

25 Jun 2015

Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

Siemens and BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, have entered into a strategic collaboration.

25 Jun 2015

Researchers develop protective vaccine against chlamydia infections

Chlamydiae are the most common, sexually transmitted, bacterial pathogens in the world. Every year around 100 million people contract Chlamydia infections, which are one of the main causes of female infertility and ectopic pregnancies and can also lead to blindness - especially in developing countries.

25 Jun 2015

Investments in cloud-based laboratory information management systems are part of Europe’s eHealth strategy

Investments in cloud-based laboratory information management systems are part of Europe’s eHealth strategy.

25 Jun 2015

TxCell’s pilot manufacturing facility activities put on temporary partial hold

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that it has temporarily put its pilot manufacturing facility activities at Besançon, France on partial hold.

24 Jun 2015

Northeastern professor receives $1.4 million NIH grant to design microfluidic devices for vaccine development

Northeastern professor of chemical engineering Shashi Murthy has received a four-year, $1.4 million award from the National Institutes of Health to develop a novel instrument that would automate an important process used in creating effective vaccines.

24 Jun 2015

Targeted molecular-imaging method could help identify early stages of prostate cancer

A targeted molecular-imaging method under development at Rochester Institute of Technology could help detect early stages of prostate cancer and improve image-directed biopsies.

23 Jun 2015

PSMA can be an ideal target for diagnosis and treatment of prostate cancer

Prostate-specific membrane antigen (PSMA) is a surface protein that is normally present on healthy prostate cells, but is found at much higher levels on prostate cancer cells. It is barely found in the rest of the body. "Therefore, PSMA is an ideal target for diagnostic purposes as well as targeted therapies against prostate cancer," says biotechnologist Dr. Matthias Eder of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ).

23 Jun 2015

Vaxon Biotech receives new patent in Japan for cancer vaccine candidates

Vaxon Biotech, a company specialized in anti-tumor immunotherapy, today announces that it has been granted a new patent in Japan. This patent covers a series of optimized cryptic peptides to be used in the design of the Vbx-026, a new cancer vaccine for solid tumors.

22 Jun 2015

ImmunoCellular, Pure MHC partner to develop new assay for ICT-107 phase 3 registrational clinical program

ImmunoCellular Therapeutics, Ltd. announced an agreement with Pure MHC, an Emergent Technologies portfolio company, for development of a novel assay for quality control that will be an important component of ImmunoCellular's ICT-107 phase 3 registrational clinical program in newly diagnosed glioblastoma, anticipated to begin in the second half of 2015.

22 Jun 2015

Planning for first clinical trial of MERS-CoV vaccine candidate now underway

Researchers from Ludwig-Maximilians-Universitaet in Munich have demonstrated, in a preclinical setting, the protective effect of a candidate vaccine directed against the coronavirus that causes Middle East Respiratory Syndrome. Planning for the first clinical trial is now underway.

22 Jun 2015

Celimmune to provide oral presentation on AMG 714 antibody at 16th International Coeliac Disease Symposium

Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, announced today that Dr. Francisco Leon, CEO and Chief Medical Officer, will provide an oral presentation on an abstract related to the company's lead product candidate, AMG 714, at the 16th International Coeliac Disease Symposium, June 24, 2015, in Prague, Czech Republic.

22 Jun 2015

Antigen News and Research

Scientists develop olfactory fingerprint test to identify individuals from sense of smell

Hepatic ALT flares linked to HBsAg clearance

Asterias Biotherapeutics added to Russell indexes

SLU's Center for Vaccine Development receives $2.9 million to study new vaccine to combat TB

Exhausted army of immune cells may damage the very body they are supposed to protect

FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease

Study opens up new line of research into origin of digestive diseases

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Ebola diagnosis now possible within minutes

Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

Researchers develop protective vaccine against chlamydia infections

Investments in cloud-based laboratory information management systems are part of Europe’s eHealth strategy

TxCell’s pilot manufacturing facility activities put on temporary partial hold

Northeastern professor receives $1.4 million NIH grant to design microfluidic devices for vaccine development

Targeted molecular-imaging method could help identify early stages of prostate cancer

PSMA can be an ideal target for diagnosis and treatment of prostate cancer

Vaxon Biotech receives new patent in Japan for cancer vaccine candidates

ImmunoCellular, Pure MHC partner to develop new assay for ICT-107 phase 3 registrational clinical program

Planning for first clinical trial of MERS-CoV vaccine candidate now underway

Celimmune to provide oral presentation on AMG 714 antibody at 16th International Coeliac Disease Symposium

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News